Stereotactic radiosurgery in the management of vestibular schwannoma:a single-institution experience
PO-1138
Abstract
Stereotactic radiosurgery in the management of vestibular schwannoma:a single-institution experience
Authors: Catarina Silva1, Marina Amorim1, M. Adelina Costa2, Graça Fonseca2, Carlos Fardilha2, João Gagean2, Sara Simões1, Fernanda Ponte2, Guilherme Campos2, Carla Seixas2, Fátima Rodrigues2, Paulo Costa1,2
1Hospital de Braga, Radiation Oncology, Braga, Portugal; 2CUF Porto Instituto - Júlia Teixeira S.A., Radiation Oncology, Porto, Portugal
Show Affiliations
Hide Affiliations
Purpose or Objective
Vestibular
schwannoma (VS) is a type of non-cancerous brain tumor. This type of tumor grows on the vestibulocochlear
nerve (cranial nerve VIII), which is responsible for control balance and
hearing. Stereotactic radiosurgery (SRS) has evolved as a first-line alternative
treatment for small VS. Our purpose was to study the outcomes of SRS using
Cyberknife (CK) in terms of tumor control, hearing and side effects in the treatment
of VS.
Material and Methods
We
retrospectively analysed the data of 28 patients with the diagnosis of VS (11
male and 17 female) who underwent treatment with Cyberknife®, between 2016 and
2021 at our institution, with a dose of 12Gy/18Gy (single fraction), 18Gy/21/24Gy
(3 fractions) and 25 Gy (5 fractions). Audiograms were performed before and
after SRS to evaluate auditory function, and the radiological tumor control was
evaluated using magnetic resonance imaging. Age, pre and postoperative tumor
size, tumor coverage, normalized conformity index and adverse events were
collected and analysed for all patients.
Results
The
mean age was 56 years (range 38–79). Mean CTV volume was 2.56 cm3 (0.14-15.04
cm3) and mean PTV volume was 3.76 cm3 (0.47-20.06 cm3).
The average conformity index was 1.21 (1.08-1.58). The PTV coverage of at least
95% was obtained by prescribing the therapeutic dose to isodose lines ranging
from 69.7 to 89.3%. The mean follow-up time was 28 months (1–65 months). Radiological
tumor control revealed that 20 patients (71%) showed a decrease of initial tumor
size, 7 patients (25%) showed stable tumor and 1 (4%) presented an initial
decrease in size but with a tumor growth 2.5 years after CK-SRS. Three (10,7%)
of 28 patients presented lost hearing prior to treatment. The 25 cases (88%)
with preserved hearing remained stable at the last follow-up. Mild adverse
events were temporarily in four patients (14%): one with CTCAE (CTCAE v5.0) grade
1 facial nerve disorder, two with grade 1 headache and one with CTCAE grade 2
facial muscle weakness. Seven (25%) patients described permanent mild symptoms:
CTCAE grade 2 without limiting daily life (vision decreased n=2) and grade 1 (facial
weakness n=3, vertigo n=2). The patients with hearing deterioration had larger
tumour volumes and poorer hearing prior to radiosurgery.
Conclusion
CyberKnife
Stereotactic Radiosurgery is an excellent alternative treatment modality for
patients with vestibular schwannoma, as is a well-tolerated and effective
regimen. Treatment goals are
long-term tumor control, hearing preservation and concurrently low
side-effects. Our results revealed
an excellent tumor
control rate and acceptable
preservation of hearing, with mild side effects, consistent with those reported
in the literature.